network member

City of Hope

1500 E. Duarte Road, Duarte, CA 91010 - USA
City of Hope_horizontal

About Network Member

City of Hope is an independent biomedical research and treatment center for cancer, diabetes, and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is the highest ranked cancer hospital in the West, according to U.S. News & World Report’s Best Hospitals: Specialty Ranking. Its main campus is located near Los Angeles, with additional locations throughout Southern California. Website: cityofhope.org
Adrine Chung, MBA,
Sr. Director, Clinical Trials Office Operations
Enrollment Closed

HCRN-GU19-385

Phase II Trial of Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)
Cancer areas:Prostate
City of Hope
Froedtert & the Medical College of Wisconsin
Knight Cancer Institute at Oregon Health & Science University
University of Michigan Rogel Cancer Center
Winship Cancer Institute of Emory University
Enrollment Closed

HCRN-GU20-444

Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing
Cancer areas:Bladder
City of Hope
Icahn School of Medicine at Mount Sinai
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
University of New Mexico Comprehensive Cancer Center
Currently Enrolling

HCRN-LYM21-544

Phase 2, open label, multicenter study of pacritinib in relapsed/refractory T-cell lymphoproliferative neoplasms
Cancer areas:Lymphoma
City of Hope
The Ohio State University
University of Michigan Rogel Cancer Center
Enrollment Closed

HCRN-GU16-257

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing
Cancer areas:Bladder
City of Hope
Huntsman Cancer Institute at the University of Utah
Icahn School of Medicine at Mount Sinai
Knight Cancer Institute at Oregon Health & Science University
Penn Medicine Abramson Cancer Center
University of Wisconsin Carbone Cancer Center
USC Norris Comprehensive Cancer Center